Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia

Current Atherosclerosis Reports

Volumn 12, Issue 1, 2010, Pages 58-65

  Thomas, Tiffany ^a   Ginsberg, Henry ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Antisense oligonucleotide; ApoB; Hyperlipidemia; LDL C; Mipomersin

Indexed keywords

ALPHA TOCOPHEROL; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHYLOMICRON; EZETIMIBE; ISIS 147764; LIPOPROTEIN A; LIPOSOME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MIPOMERSEN; SIMVASTATIN; SMALL INTERFERING RNA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; OLIGONUCLEOTIDE;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTISENSE THERAPY; ATHEROSCLEROSIS; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG LIVER LEVEL; DRUG SAFETY; DRUG TISSUE LEVEL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPOBETALIPOPROTEINEMIA; FLU LIKE SYNDROME; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INSULIN RESISTANCE; LIPID STORAGE; LIPOGENESIS; LIPOPROTEIN SYNTHESIS; MALABSORPTION; MUSCLE FATIGUE; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG DESIGN; HYPERLIPIDEMIAS; LIVER; METABOLISM; SECRETION (PROCESS);

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; DRUG DESIGN; HUMANS; HYPERLIPIDEMIAS; LIVER; OLIGONUCLEOTIDES; HYPOLIPIDEMIC AGENTS;

EID: 77149160366     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0078-7     Document Type: Review

References (46)

1. Anderson RN, Kochanek KD, Murphy SL: Report of final mortality statistics, 1995. Monthly Vital Stat Rep 1997, 45 (11 Suppl 2) :1-79.
2. Xu J, Kochanek KD, Tejada-Vera B: Deaths: preliminary data for 2007. National Vital Stat Rep 2009, 58:1-51.
3. Versmissen J, Oosterveer DM, Yazdanpanah M, et al.: Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008, 337:a2423.
4. Law MR, Wald NJ, Thompson SG: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994, 308:367-372.
5. Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006, 97:52C-60C.
6. Smiley WH, Khan BV, Sperling LS: Management of the statin-intolerant patient. Curr Treat Options Cardiovasc Med 2009, 11:263-271.
7. Hou R, Goldberg AC: Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am 2009, 38:79-97.
8. Young SG: Recent progress in understanding apolipoprotein B. Circulation 1990, 82:1574-1594.
9. Davidson NO, Shelness GS: Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000, 20:169-193.
10. Farese RV Jr, Ruland SL, Flynn LM, et al.: Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. Proc Natl Acad Sci USA 1995, 92:1774-1778.
11. Lin X, Schonfeld G, Yue P, et al.: Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation. Arterioscler Thromb Vasc Biol 2002, 22:476-482.
12. Srivastava RA, Toth L, Srivastava N, et al.: Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knockout mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB. Mol Cell Biochem 1999, 202:37-46.
13. Linton MF, Farese RV Jr, Young SG: Familial hypobetalipoproteinemia. J Lipid Res 1993, 34:521-541.
14. Schonfeld G, Patterson BW, Yablonskiy DA, et al.: Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res 2003, 44:470-478.
15. Tanoli T, Yue P, Yablonskiy D, et al.: Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res 2004, 45:941-947.
16. Sankatsing RR, Fouchier SW, de Haan S, et al.: Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2005, 25:1979-1984.
17. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, et al.: The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu Rev Nutr 2000, 20:663-697.
18. Raabe M, Flynn LM, Zlot CH, et al.: Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc Natl Acad Sci USA 1998, 95:8686-8691.
19. Parhofer KG, Barrett PH: Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies. J Lipid Res 2006, 47:1620-1630.
20. Tybjaerg-Hansen A, Gallagher J, Vincent J, et al.: Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 1990, 80:235-242.
21. Tybjaerg-Hansen A, Steffensen R, Meinertz H, et al.: Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 1998, 338:1577-1584.
22. Kurreck J: Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003, 270:1628-1644.
23. Crooke ST: Progress in antisense technology. Annu Rev Med 2004, 55:61-95.
24. Campbell JM, Bacon TA, Wickstrom E: Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Methods 1990, 20:259-267.
25. Crooke ST: Progress in antisense technology: the end of the beginning. Methods Enzymol 2000, 313:3-45.
26. Brown DA, Kang SH, Gryaznov SM, et al.: Effect of phosphor-othioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994, 269:26801-26805.
27. Guvakova MA, Yakubov LA, Vlodavsky I, et al.: Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995, 270:2620-2627.
28. Manoharan M: 2′-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta 1999, 1489:117-130.
29. Crooke RM: Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin Biol Ther 2005, 5:907-917.
30. • Yu RZ, Kim TW, Hong A, et al.: Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 2007, 35:460-468. This study provides evidence that ASOs quickly distribute to peripheral tissues, including the liver, but not the central nervous system. Subcutaneous injection appears to be an effective method for ASO delivery.
31. Yu RZ, Lemonidis KM, Graham MJ, et al.: Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009, 77:910-919.
32. Crooke RM, Graham MJ, Lemonidis KM, et al.: An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005, 46:872-884.
33. Preiss D, Sattar N: Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008, 115:141-150.
34. Hirano K, Young SG, Farese RV Jr, et al.: Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48. J Biol Chem 1996, 271:9887-9890.
35. Mullick AE, Graham MJ, Crooke RM: Antisense inhibition of apolipoprotein b ameliorated diet-induced hypercholesterolemia and reduced atherosclerosis in ldl receptor-deficient mice. Presented at Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2008. Atlanta, GA; April 16-18, 2008.
36. Merki E, Graham MJ, Mullick AE, et al.: Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein (a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein (a) transgenic mice. Circulation 2008, 118:743-753.
37. ClinicalTrials.gov: Available at http://www.clinicaltrials.gov/ct2/ results?term=301012. Accessed September 15, 2009.
38. Update from Mipomersen extended dosing study continues to show that Mipomersen is well tolerated and maintains activity in patients treated for up to 16 months [press release]. Carlsbad, CA: Isis Pharmaceuticals; April 14, 2008.
39. Percent LDL-C reduction in very high-risk patient population [press release]. Carlsbad, CA: Isis Pharmaceuticals; May 20, 2009.
40. Kastelein JJ, Wedel MK, Baker BF, et al.: Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114:1729-1735.
41. Isis reports new data for Mipomersen in routine high cholesterol patients and provides cumulative safety summary [press release]. Carlsbad, CA: Isis Pharmaceuticals; Nov. 13, 2007.
42. Yu RZ, Geary RS, Flaim JD, et al.: Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009, 48:39-50.
43. Khoo B, Roca X, Chew SL, et al.: Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB. BMC Mol Biol 2007, 8:3.
44. Soutschek J, Akinc A, Bramlage B, et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
45. Nishina K, Unno T, Uno Y, et al.: Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 2008, 16:734-740.
46. Zimmermann TS, Lee AC, Akinc A, et al.: RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.